No 01 2017

The agreement, building on a letter of intent announced earlier this year, is intended to establish a long-term partnership in spray-dried formulations, a technology considered important for the development of inhalable drug formulations for biologics, vaccines, and other large molecules.

A newly approved EUR 2.8 million project will, over the next three years, bring together leading organizations from Sweden, Denmark and Norway to accelerate commercialization, investment and market access for companies developing solutions in women's health.

Following the outcome of the DIAGNODE-3 study, the company’s immediate priority is to complete the close-out of the Phase 3 program in an efficient and responsible manner, it states.

The partnership will leverage Combotope’s SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.

CHOSA Oncology has established a business presence in Boston, Massachusetts, marking an important strategic step in the company's US commercialization for Platin-DRP.

Stratipath Breast has received CE marking under the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), the EU's most stringent regulatory framework for in vitro diagnostic medical devices.

Elicera Therapeutics held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company’s iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.